Alto Neuroscience
Los Altos, United States · Biotechnology, Health Care · 76 employees
Alto Neuroscience is a biopharmaceutical company redefining psychiatry through its Precision Psychiatry Platform™, which leverages individuals’ neurobiology to develop personalized and highly effective medicines that help patients get better faster. By integrating biomarkers such as EEG and wearable data, behavioral patterns, genetics, and other biological factors, Alto uses AI-driven insights to
Funding history
- Post-IPO Equity · $120.0M · Mar 2026
- Venture - Series Unknown · $50.0M · Oct 2025
- Venture - Series Unknown · $59.3M · Nov 2023
- Venture - Series Unknown · $45.0M · Nov 2023
- Venture - Series Unknown · $31.9M · Nov 2023
Recent signals
- Aug 27, 2026: Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
- Mar 16, 2026: Raised $120.0M in Post-IPO Equity
- Oct 27, 2025: Raised $50.0M in Venture - Series Unknown
- Jul 01, 2025: Alto Neuroscience acquires ALTO-207 for depression treatment
- Dec 11, 2024: Launched Alto Neuroscience Presents Data at the 63rd Annual Meeting of the American College of Neuropsychopharmacology Highlighting Progress in Precision Psychiatry.
- May 21, 2024: Alto Names Michael Hanley as Chief Operating Officer
- Nov 27, 2023: Raised $59.3M in Venture - Series Unknown
- Nov 27, 2023: Raised $45.0M in Venture - Series Unknown
See plans & pricing → Track Alto Neuroscience’s funding, hiring and signals, with verified contacts, on Fundz.
Fundz watches Alto Neuroscience across 18 signal types, from funding and M&A to exec moves and hiring.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.